Neuropsychiatric Adverse Events With Ritonavir-Boosted Darunavir Monotherapy in HIV-Infected Individuals: A Randomised Prospective Study

Winston, Alan; Fätkenheuer, Gerd; Arribas, Jose; Hill, Andrew; van Delft, Yvon; Moecklinghoff, Christiane
May 2010
HIV Clinical Trials;May/Jun2010, Vol. 11 Issue 3, p163
Academic Journal
Background: Protease inhibitor monotherapy is an attractive treatment option for HIV-infected subjects. Data assessing neuropsychiatric events with the use of protease inhibitor monotherapy are sparse. Methods: Clinician- and patient-reported neuropsychiatric events were assessed over 48 weeks in HIV-infected subjects on stable antiretroviral therapy, with a plasma HIV RNA <50 copies/mL, randomised to commence on a one to one basis darunavir/ritonavir (800/100 mg once daily) alone (DRVrMono) or with nucleoside analogues (DRVrNRTI). Patient-reported events were assessed by the Functional Assessment of HIV Infection (FAHI) questionnaire and included an assessment of cognitive function. Results: Of 256 subjects enrolled, clinician-reported grade 1–4 adverse events of the nervous system (all cause) were seen in 16% of patients in each treatment arm. FAHI questionnaires were completed by 206 subjects at 48 weeks. No differences in cognitive functioning or other FAHI scores were observed between study treatment groups: Cognitive Functioning score [mean (SD)] 8.9 (2.4) and 9.0 (2.6) in DRVrMono arm and 8.8 (2.6) and 8.9 (2.8) in DRVrNRTI arm at baseline and week 48, respectively (P value for difference = .76). Conclusion: In this exploratory analysis, no differences in the evolution of neuropsychiatric adverse events over 48 weeks are observed in HIV-infected subjects randomised to switch antiretroviral therapy to darunavir/ritonavir with or without nucleoside reverse transcriptase inhibitors.


Related Articles

  • Hyperlipidemia Associated with the Use of Protease Inhibitors. Smith, John H.; Martin, Gregory J.; Decker, Catherine F. // Clinical Infectious Diseases;7/1/2000, Vol. 31 Issue 1, p207 

    Comments on an article by A.D. Roberts, R.A. Muesing, D.M. Parenti, J. Hsia, A.G. Wasserman, G.L. Simon's about alterations in lipid metabolism in HIV-infected patients receiving indinavir. Development of hyperlipidemia with the use of other available protease inhibitors; Lipid profiles of the...

  • HIV-1 Protease Inihibitors. Eron Jr., Joseph J. // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS160 

    Focuses on the role of protease inhibitors (PI) in the antiretroviral therapy for HIV-1 infected patients. Potent activity in vitro of five United States Food and Drug Administration-approved PI agents; Suppression of HIV-1 replication by PI agents with two nucleoside analogue reverse...

  • Recurrent Panniculitis in a Patient Receiving Protease Inhibitor Therapy for Human Immunodeficiency Virus Infection. Popp, Adrian I.; Armstrong, Donald; Sepkowitz, Kent A. // Clinical Infectious Diseases;10/1/1999, Vol. 29 Issue 4, p936 

    Presents a case study of panniculitis, an inflammation of the subcutaneous fats, in an HIV-infected patient receiving protease inhibitor therapy. Review of related literature; Overview of the disease; Clinical history of the patient; Treatment.

  • Long-Term Probability of Detecting Drug-Resistant HIV in Treatment-Naive Patients Initiating Combination Antiretroviral Therapy.  // Clinical Infectious Diseases;5/1/2010, Vol. 50 Issue 9, p1275 

    Background. Robust long-term estimates of the risk of development of drug resistance are needed for human immunodeficiency virus (HIV)-infected patients starting combination antiretroviral therapy (cART) regimens currently used in routine clinical practice. Methods. We followed a large cohort of...

  • Management of the Adverse Effects of Antiretroviral Therapy and Medication Adherence. Max, Blake; Sherer, Renslow // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS96 

    Examines the therapeutic agents included in the highly active antiretroviral therapy (HAART) for the treatment of patients with HIV infections. Link between poor adherence and failure of antiretroviral therapy; Threat of short term-adverse effects to successful introduction and maintenance of...

  • The changing therapeutic landscape for hepatitis C. Dore, Gregory J. // Medical Journal of Australia;6/4/2012, Vol. 196 Issue 10, p629 

    The article discusses developments in the treatment of hepatitis C virus (HCV) infection in Australia. Recent developments in direct-acting antiviral (DAA) therapy are reported. The challenges of the initial clinical use of HCV protease inhibitors are identified. Recommendations for using DAA...

  • Concurrent Use of Antiretrovirals and Anticonvulsants in Human Immunodeficiency Virus (HIV) Seropositive Patients. Romanelli, Frank; Pomeroy, Claire // Current Pharmaceutical Design;Jul2003, Vol. 9 Issue 18, p1433 

    Seizure disorders may complicate HIV disease, either as a direct result of HIV or as a manifestation of a secondary opportunistic infection. Unless a reversible cause of seizure activity can be discerned, current treatment guidelines recommend the use of anticonvulsant drugs in these patients....

  • The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa. Ataher, Quazi; Portsmouth, Simon; Napolitano, Laura A.; Eng, Sybil; Greenacre, Anna; Kambugu, Andrew; Wood, Robin; Badal-Faesen, Sharlaa; Tressler, Randy // Journal of the International AIDS Society;2012, Vol. 15 Issue 1, p1 

    Background: The introduction of C-C chemokine receptor type-5 (CCR5) antagonists as antiretroviral therapy has led to the need to study HIV co-receptor tropism in different HIV-1 subtypes and geographical locations. This study was undertaken to evaluate HIV-1 co-receptor tropism in the...

  • The pharmacogenomics of HIV therapy. Pirmohamed, M.; Back, D.J. // Pharmacogenomics Journal;2001, Vol. 1 Issue 4, p243 

    Examines the potential areas where pharmacogenomics of HIV therapy may be of use in maximizing the efficacy and minimizing the toxicity of antiretrovirals. Classes of licensed antiretrovirals; Need for HIV patients to commence therapy with a highly active antiretroviral therapy regimen;...

  • VIRAL IMMUNITY: IFN-γ embargo. Buckland, Jenny // Nature Reviews Immunology;Apr2002, Vol. 2 Issue 4, p221 

    Discusses research being done on the antiviral interferon-γ response of HIV-infected individual. Reference to a study by M.L. Garba and colleagues, published in the 2002 issue of the 'Journal of Immunology'; Factor that caused the reduced interferon-γ responses in suppressors; Significance...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics